{"id":"da-6034","safety":{"commonSideEffects":[{"rate":null,"effect":"Muscle pain or myalgia"},{"rate":null,"effect":"Gastrointestinal disturbances"},{"rate":null,"effect":"Elevated liver enzymes"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"DA-6034 activates PPARδ, a nuclear receptor involved in fatty acid oxidation and glucose homeostasis. By selectively targeting PPARδ, the drug promotes beneficial metabolic changes and anti-inflammatory effects, potentially improving dyslipidemia and metabolic dysfunction. This mechanism differs from pan-PPAR agonists by offering more selective tissue effects with potentially improved safety.","oneSentence":"DA-6034 is a selective agonist of the peroxisome proliferator-activated receptor delta (PPARδ) that enhances lipid metabolism and reduces inflammation.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:08:30.114Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Dyslipidemia"},{"name":"Metabolic syndrome"}]},"trialDetails":[{"nctId":"NCT01162954","phase":"PHASE1","title":"Phase I Study to Evaluate the Tolerability of Eye Drop DA-6034 in Healthy Volunteers","status":"COMPLETED","sponsor":"Dong-A ST Co., Ltd.","startDate":"2008-09","conditions":"Dry Eye Syndrome","enrollment":""},{"nctId":"NCT01670357","phase":"PHASE2","title":"Phase II Study of DA-6034 Eye Drops in Dry Eye Syndrome","status":"COMPLETED","sponsor":"Dong-A ST Co., Ltd.","startDate":"2012-04","conditions":"Dry Eye Syndrome","enrollment":150},{"nctId":"NCT01813812","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and Safety of DA-6034 and to Demonstrate the Non-inferiority of DA-6034","status":"UNKNOWN","sponsor":"Dong-A Pharmaceutical Co., Ltd.","startDate":"2010-10","conditions":"Acute Gastritis, Chronic Gastritis","enrollment":492}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":18,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Placebo"],"phase":"phase_3","status":"active","brandName":"DA-6034","genericName":"DA-6034","companyName":"Dong-A ST Co., Ltd.","companyId":"dong-a-st-co-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"DA-6034 is a selective agonist of the peroxisome proliferator-activated receptor delta (PPARδ) that enhances lipid metabolism and reduces inflammation. Used for Dyslipidemia, Metabolic syndrome.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}